These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50 related articles for article (PubMed ID: 10208644)
1. High yield purification and characterization of engineered human P450 1A2 and generation of immuno-inhibitor antibodies. Louërat-Oriou B; Flinois JP; Beaune PH; Pompon D Pharmacogenetics; 1999 Feb; 9(1):61-70. PubMed ID: 10208644 [TBL] [Abstract][Full Text] [Related]
2. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Dong MS; Yamazaki H; Guo Z; Guengerich FP Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680 [TBL] [Abstract][Full Text] [Related]
3. Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein. Parikh A; Guengerich FP Protein Expr Purif; 1997 Apr; 9(3):346-54. PubMed ID: 9126606 [TBL] [Abstract][Full Text] [Related]
4. Expression of CYP71B7, a cytochrome P450 expressed sequence Tag from Arabidopsis thaliana. Maughan JA; Nugent JH; Hallahan DL Arch Biochem Biophys; 1997 May; 341(1):104-11. PubMed ID: 9143359 [TBL] [Abstract][Full Text] [Related]
5. Purification, molecular cloning, heterologous expression and characterization of pig CYP1A2. Messina A; Chirulli V; Gervasi PG; Longo V Xenobiotica; 2008 Dec; 38(12):1453-70. PubMed ID: 18949657 [TBL] [Abstract][Full Text] [Related]
6. Effects of N-terminal modification of recombinant human cytochrome P450 1A2 on catalytic activity. Kim HJ; Lee SB; Guengerich FP; Park YI; Dong MS Xenobiotica; 2007 Apr; 37(4):356-65. PubMed ID: 17455110 [TBL] [Abstract][Full Text] [Related]
7. Molecular cloning and functional analysis of cytochrome P450 1A2 from Japanese monkey liver: comparison with marmoset cytochrome P450 1A2. Narimatsu S; Oda M; Hichiya H; Isobe T; Asaoka K; Hanioka N; Yamano S; Shinoda S; Yamamoto S Chem Biol Interact; 2005 Feb; 152(1):1-12. PubMed ID: 15766918 [TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Parikh A; Josephy PD; Guengerich FP Biochemistry; 1999 Apr; 38(17):5283-9. PubMed ID: 10220313 [TBL] [Abstract][Full Text] [Related]
9. High-level expression of human cytochrome P450 1A2 by co-expression with human molecular chaperone HDJ-1(Hsp40). Ahn T; Yang S; Yun CH Protein Expr Purif; 2004 Jul; 36(1):48-52. PubMed ID: 15177283 [TBL] [Abstract][Full Text] [Related]
10. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Liu J; Ericksen SS; Sivaneri M; Besspiata D; Fisher CW; Szklarz GD Arch Biochem Biophys; 2004 Apr; 424(1):33-43. PubMed ID: 15019834 [TBL] [Abstract][Full Text] [Related]
11. Bacterial expression and purification of the Arabidopsis NADPH-cytochrome P450 reductase ATR2. Hull AK; Celenza JL Protein Expr Purif; 2000 Apr; 18(3):310-5. PubMed ID: 10733884 [TBL] [Abstract][Full Text] [Related]
12. Functional expression in Bacillus subtilis of mammalian NADPH-cytochrome P450 oxidoreductase and its spore-display. Yim SK; Jung HC; Yun CH; Pan JG Protein Expr Purif; 2009 Jan; 63(1):5-11. PubMed ID: 18678259 [TBL] [Abstract][Full Text] [Related]
13. Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Sandhu P; Guo Z; Baba T; Martin MV; Tukey RH; Guengerich FP Arch Biochem Biophys; 1994 Feb; 309(1):168-77. PubMed ID: 8117105 [TBL] [Abstract][Full Text] [Related]
14. Chimeras of the human cytochrome P450 1A family produced in yeast. Accumulation in microsomal membranes, enzyme kinetics and stability. Bellamine A; Gautier JC; Urban P; Pompon D Eur J Biochem; 1994 Nov; 225(3):1005-13. PubMed ID: 7957192 [TBL] [Abstract][Full Text] [Related]
15. Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5' substitution, stabilization, purification, spectral characterization, and catalytic properties. Guo Z; Gillam EM; Ohmori S; Tukey RH; Guengerich FP Arch Biochem Biophys; 1994 Aug; 312(2):436-46. PubMed ID: 8037457 [TBL] [Abstract][Full Text] [Related]
16. Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta. Czekaj P; Wiaderkiewicz A; Florek E; Wiaderkiewicz R Arch Toxicol; 2005 Jan; 79(1):13-24. PubMed ID: 15448981 [TBL] [Abstract][Full Text] [Related]
17. Development of an on-line high performance liquid chromatography detection system for human cytochrome P450 1A2 inhibitors in extracts of natural products. Jeurissen SM; Claassen FW; Havlik J; Bouwmans EE; Cnubben NH; Sudhölter EJ; Rietjens IM; van Beek TA J Chromatogr A; 2007 Feb; 1141(1):81-9. PubMed ID: 17184784 [TBL] [Abstract][Full Text] [Related]
18. Purification of recombinant wheat cytochrome P450 monooxygenase expressed in yeast and its properties. Wen-Sheng X; Xiang-Jing W; Tian-Rui R; Su-Qin C Protein Expr Purif; 2006 Jan; 45(1):54-9. PubMed ID: 16122941 [TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of human cytochrome P450 1A2 by co-expression with human molecular chaperone Hsp70. Ahn T; Yang S; Yun CH Toxicol Lett; 2004 Nov; 153(2):267-72. PubMed ID: 15451558 [TBL] [Abstract][Full Text] [Related]
20. Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli. Kim DH; Kim KH; Isin EM; Guengerich FP; Chae HZ; Ahn T; Yun CH Protein Expr Purif; 2008 Feb; 57(2):188-200. PubMed ID: 18032064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]